---
figid: PMC7499473__fonc-10-01672-g0001
figlink: pmc/articles/PMC7499473/figure/F1/
number: Figure 1
caption: 'Targeting CXCR4. (A) Overview of CXCL12/CXCR4 signal transduction pathways.
  CXCR4 is a seven-transmembrane spanning G-protein coupled receptor. Upon binding
  CXCL12, CXCR4 G-protein-mediated signaling leads to (a) activation of JAK/STAT signaling
  promoting stemness and survival, (b) activation of the phosphatidylinositol-3-kinase
  (PI3K)-Akt-mTOR pathway promoting cell survival and proliferation, (c) activation
  of Ras/Raf and mitogen-activated protein kinase (MAPK) signaling leading to phosphorylation
  of extracellular signal-regulated kinase (ERK) 1/2 which promotes survival and proliferation,
  (d) activation of phospholipase C (PLC) leading to diacylglycerol (DAG) and inositol
  triphosphate (IP3) production which induces Ca2+ efflux and protein kinase C (PKC)
  activation resulting in chemotaxis and migration, and (e) inhibition of adenylyl
  cyclase (AC), which reduces cAMP production and protein kinase A activation leading
  to reduced cell proliferation and chemotaxis. CXCL12 also induces CXCR4 desensitization
  via uncoupling the receptor from G-proteins by GRK-dependent phosphorylation and
  subsequent β-arrestin-dependent endocytosis and lysosomal degradation. (B) Inhibitors
  of the CXCR4/CXCL12 axis. Drugs targeting CXCR4 can be divided into three general
  categories: (1) small molecules; (2) peptide-like molecules; and (3) antibodies.
  NOX-A12 disrupts the CXCR4/CXCL12 axis by binding and neutralizing CXCL12. (C) Schematic
  of CXCR4 inhibitor-mediated chemosensitization in leukemia. Osteoblasts, mesenchymal
  stem/stromal cells (MSC) and CXCL12-abundant reticular (CAR) cells in the bone marrow
  niche constitutively express CXCR12 leading to the recruitment and adhesion of CXCR4-expressing
  leukemia cells. These interactions provide a protective environment to the malignant
  cells in the presence of chemotherapeutic agents. Disruption of CXCR4-mediated adhesion
  of leukemia cells to the chemoprotective cells in the bone marrow niche via administration
  of CXCR4 inhibitors promotes mobilization and chemosensitization of leukemia cells.
  (D) Alternative approaches to target CXCR4-expressing cells. Antibodies to CXCR4
  have been linked to cytotoxic drugs (antibody-drug conjugates; ADC) which induce
  cell death via DNA damage and/or microtubule disruption upon internalization. Several
  small molecule inhibitors and peptide-based antagonists of CXCR4 have been radiolabeled
  for positron emission tomography (PET) imaging or endoradiotherapy. Nanomaterials
  are small particles that serve as carriers for small-molecule drugs, proteins, and
  nucleic acids. Several nanomaterials targeting CXCR4 with the small molecule inhibitors,
  antibodies, or peptide-based antagonists discussed above have been developed.'
pmcid: PMC7499473
papertitle: Targeting CXCR4 in AML and ALL.
reftext: Daniel Cancilla, et al. Front Oncol. 2020;10:1672.
pmc_ranked_result_index: '120398'
pathway_score: 0.9066445
filename: fonc-10-01672-g0001.jpg
figtitle: Targeting CXCR4
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7499473__fonc-10-01672-g0001.html
  '@type': Dataset
  description: 'Targeting CXCR4. (A) Overview of CXCL12/CXCR4 signal transduction
    pathways. CXCR4 is a seven-transmembrane spanning G-protein coupled receptor.
    Upon binding CXCL12, CXCR4 G-protein-mediated signaling leads to (a) activation
    of JAK/STAT signaling promoting stemness and survival, (b) activation of the phosphatidylinositol-3-kinase
    (PI3K)-Akt-mTOR pathway promoting cell survival and proliferation, (c) activation
    of Ras/Raf and mitogen-activated protein kinase (MAPK) signaling leading to phosphorylation
    of extracellular signal-regulated kinase (ERK) 1/2 which promotes survival and
    proliferation, (d) activation of phospholipase C (PLC) leading to diacylglycerol
    (DAG) and inositol triphosphate (IP3) production which induces Ca2+ efflux and
    protein kinase C (PKC) activation resulting in chemotaxis and migration, and (e)
    inhibition of adenylyl cyclase (AC), which reduces cAMP production and protein
    kinase A activation leading to reduced cell proliferation and chemotaxis. CXCL12
    also induces CXCR4 desensitization via uncoupling the receptor from G-proteins
    by GRK-dependent phosphorylation and subsequent β-arrestin-dependent endocytosis
    and lysosomal degradation. (B) Inhibitors of the CXCR4/CXCL12 axis. Drugs targeting
    CXCR4 can be divided into three general categories: (1) small molecules; (2) peptide-like
    molecules; and (3) antibodies. NOX-A12 disrupts the CXCR4/CXCL12 axis by binding
    and neutralizing CXCL12. (C) Schematic of CXCR4 inhibitor-mediated chemosensitization
    in leukemia. Osteoblasts, mesenchymal stem/stromal cells (MSC) and CXCL12-abundant
    reticular (CAR) cells in the bone marrow niche constitutively express CXCR12 leading
    to the recruitment and adhesion of CXCR4-expressing leukemia cells. These interactions
    provide a protective environment to the malignant cells in the presence of chemotherapeutic
    agents. Disruption of CXCR4-mediated adhesion of leukemia cells to the chemoprotective
    cells in the bone marrow niche via administration of CXCR4 inhibitors promotes
    mobilization and chemosensitization of leukemia cells. (D) Alternative approaches
    to target CXCR4-expressing cells. Antibodies to CXCR4 have been linked to cytotoxic
    drugs (antibody-drug conjugates; ADC) which induce cell death via DNA damage and/or
    microtubule disruption upon internalization. Several small molecule inhibitors
    and peptide-based antagonists of CXCR4 have been radiolabeled for positron emission
    tomography (PET) imaging or endoradiotherapy. Nanomaterials are small particles
    that serve as carriers for small-molecule drugs, proteins, and nucleic acids.
    Several nanomaterials targeting CXCR4 with the small molecule inhibitors, antibodies,
    or peptide-based antagonists discussed above have been developed.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CXCR4
  - SMN1
  - CXCL12
  - GRK3
  - GRK4
  - GRK6
  - GRK1
  - GRK7
  - GRK2
  - GRK5
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - HRAS
  - KRAS
  - NRAS
  - PLCB3
  - PLCB4
  - PLCG1
  - PLCB1
  - PLCE1
  - PLCD4
  - PLCD3
  - PLCB2
  - PLCD1
  - PLCG2
  - PLCZ1
  - ADCY2
  - ADCY3
  - ADCY5
  - ADCY6
  - ADCY8
  - ADCY9
  - ADCY10
  - ADCY4
  - ADCY1
  - ADCY7
  - STAT1
  - STAT5A
  - STAT6
  - STAT2
  - STAT3
  - STAT4
  - STAT5B
  - AKT2
  - AKT3
  - AKT1
  - ARAF
  - BRAF
  - RAF1
  - DAG1
  - MTOR
  - PRKACG
  - PRKAR1A
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKAR1B
  - MSC
  - AMD11070
  - PF-06747143
  - LY2510924
  - O
  - Stemness
  - leukemia
  - Cytotoxic
genes:
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: Small
  symbol: SMA2
  source: hgnc_alias_symbol
  hgnc_symbol: SMN1
  entrez: '6606'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK3
  entrez: '157'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK4
  entrez: '2868'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK6
  entrez: '2870'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK1
  entrez: '6011'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK7
  entrez: '131890'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK2
  entrez: '156'
- word: GRK
  symbol: GRK
  source: bioentities_symbol
  hgnc_symbol: GRK5
  entrez: '2869'
- word: CXCR4'
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT6
  entrez: '6778'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT4
  entrez: '6775'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: DAG/IP3
  symbol: DAG
  source: hgnc_alias_symbol
  hgnc_symbol: DAG1
  entrez: '1605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: РКА
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: схсL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: MSC
  symbol: MSC
  source: hgnc_symbol
  hgnc_symbol: MSC
  entrez: '9242'
- word: CXCL12-
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4"
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
chemicals:
- word: AMD11070
  source: MESH
  identifier: C494414
- word: PF-06747143
  source: MESH
  identifier: D010977
- word: LY2510924
  source: MESH
  identifier: C000595455
- word: O
  source: MESH
  identifier: D013481
diseases:
- word: Stemness
  source: MESH
  identifier: D020295
- word: leukemia
  source: MESH
  identifier: D007938
- word: Cytotoxic
  source: MESH
  identifier: D064420
---
